Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Femasys Inc (FEMY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/11/2025: FEMY (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7.25
1 Year Target Price $7.25
| 2 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 29.17% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 07/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 30.08M USD | Price to earnings Ratio - | 1Y Target Price 7.25 |
Price to earnings Ratio - | 1Y Target Price 7.25 | ||
Volume (30-day avg) 4 | Beta -2.61 | 52 Weeks Range 0.69 - 1.80 | Updated Date 07/12/2025 |
52 Weeks Range 0.69 - 1.80 | Updated Date 07/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.91 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1600.11% |
Management Effectiveness
Return on Assets (TTM) -65.69% | Return on Equity (TTM) -239.87% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 33925902 | Price to Sales(TTM) 17.7 |
Enterprise Value 33925902 | Price to Sales(TTM) 17.7 | ||
Enterprise Value to Revenue 19.97 | Enterprise Value to EBITDA 0.24 | Shares Outstanding 32526200 | Shares Floating 24373977 |
Shares Outstanding 32526200 | Shares Floating 24373977 | ||
Percent Insiders 10.57 | Percent Institutions 12.06 |
Upturn AI SWOT
Femasys Inc
Company Overview
History and Background
Femasys Inc. is a biomedical company focused on developing solutions in women's healthcare. Founded in 2004, it has centered its efforts on addressing unmet needs in permanent contraception and fertility solutions. The company has evolved from initial research and development stages to commercialization and continued innovation.
Core Business Areas
- Permanent Contraception: Focuses on developing and marketing the FemaSeedu00ae System, a non-surgical, in-office solution for permanent contraception. It involves delivering sperm to the fallopian tube to block it from being fertilised.
- Fertility Solutions: Developing solutions such as FemaCath and FemVue to improve fertility outcomes through advanced diagnostics and treatment.
Leadership and Structure
The leadership team includes individuals with extensive experience in medical devices, biotechnology, and finance. The organizational structure consists of departments responsible for research and development, regulatory affairs, sales and marketing, and operations. Crystal Denlinger is the President and CEO.
Top Products and Market Share
Key Offerings
- FemaSeedu00ae System: A non-surgical method of permanent birth control for women. It is designed to be administered in an office setting, offering a less invasive alternative to traditional surgical methods. The market share data is still developing, but the main competitor is Essure, before Bayer removed Essure off the market. Bayer (BAYRY) and CooperSurgical are the main competitors now.
- FemVueu00ae: A saline-contrast ultrasound for fallopian tube assessment used during fertility evaluations. It offers an alternative to hysterosalpingography (HSG). Market share data is being developed as more clinics adopt this product. The competitor is HSG. The number of users is increasing as more clinics are adopting it.
Market Dynamics
Industry Overview
The women's healthcare market is characterized by increasing demand for less invasive procedures and improved fertility solutions. Driven by technological advancements and shifts in patient preferences, there is a growing focus on convenience and reduced recovery times.
Positioning
Femasys Inc. aims to be a leader in women's healthcare by offering innovative, less invasive solutions. Their competitive advantage lies in their non-surgical approach to permanent contraception and advancements in fertility diagnostics.
Total Addressable Market (TAM)
The TAM for permanent contraception and fertility solutions is estimated to be several billion dollars globally. Femasys Inc. is positioned to capture a portion of this market by providing accessible and innovative solutions. The market value is estimated between 8 billion and 12 billion annually. Femasys Inc. current market is small but potentially poised to grow in a sustainable fashion.
Upturn SWOT Analysis
Strengths
- Innovative technology
- Non-surgical solutions
- In-office procedures
- Focused on women's healthcare
Weaknesses
- Limited market penetration
- Reliance on single product (FemaSeed)
- Regulatory hurdles
- Competition from established players
Opportunities
- Expanding product portfolio
- Entering new geographic markets
- Strategic partnerships
- Increasing awareness of non-surgical options
Threats
- Changing regulatory landscape
- Technological disruptions
- Product liability risks
- Economic downturn
Competitors and Market Share
Key Competitors
- BAYRY
- COOP
Competitive Landscape
Femasys Inc. differentiates itself through non-surgical, in-office solutions. However, it faces competition from larger, more established companies with greater market reach and resources. The company needs to continue to demonstrate the clinical benefits and cost-effectiveness of its products to gain market share.
Growth Trajectory and Initiatives
Historical Growth: Requires access to financial databases which I do not have.
Future Projections: Future projections require access to analyst estimates, which I do not have access to.
Recent Initiatives: Recent initiatives include expanding the sales and marketing efforts for FemaSeed and FemVue, as well as continuing research and development of new products.
Summary
Femasys Inc. is a biomedical company innovating in women's healthcare with non-surgical solutions for contraception and fertility. While possessing innovative technology, it faces challenges in market penetration and competition. Future growth depends on expanding its product portfolio, entering new markets, and overcoming regulatory hurdles. The company's success hinges on demonstrating the clinical and economic benefits of its unique offerings.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Femasys Inc. website
- Company press releases
- Industry reports
Disclaimers:
The data provided is for informational purposes only and should not be considered financial advice. Market share data and projections are estimates and may vary. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Femasys Inc
Exchange NASDAQ | Headquaters Suwanee, GA, United States | ||
IPO Launch date 2021-06-18 | Founder, President, CEO & Director Ms. Kathy Lee-Sepsick M.B.A. | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 69 | Website https://www.femasys.com |
Full time employees 69 | Website https://www.femasys.com | ||
Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination solution; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; FemCath, a cornual balloon catheter for selective fallopian tube evaluation; and FemChec, a controlled contrast-generating device for fallopian tube diagnosis. It also develops FemBloc, a non-surgical permanent birth control solution. The company offers its products to reproductive endocrinologists, gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.